Worldwide, approximately 500-800 million women are infected with Mycobacterium tuberculosis, and 3.2 million develop active tuberculosis annually, at least 216 000 during pregnancy, and 480 000 die [1, 2] . Tuberculosis is a leading causes of death in women of childbearing age (15-44 years) , and, if untreated, a common cause of nonobstetric maternal mortality [3] [4] [5] [6] , pregnancy complications, and infant mortality [4] [5] [6] [7] [8] [9] . Women of childbearing age are more likely than men to progress from latent tuberculosis infection (LTBI) to active tuberculosis, possibly owing to immune changes associated with pregnancy and higher rates of human immunodeficiency virus (HIV) infection [1, 10, 11] . However, tuberculosis prevention and treatment during pregnancy poses challenges, particularly in the setting of HIV coinfection.
Several physiologic adaptations occur throughout pregnancy, which peak in the third trimester and significantly affect drug disposition (Supplementary Figure 1) [12, 13] . The safety and efficacy of individual or multidrug regimens for pregnant women cannot be predicted without clinical trials, yet safety and pharmacokinetic (PK) data during pregnancy are lacking for many tuberculosis drugs. Importantly, pregnant women continue to be excluded from new tuberculosis drug trials, limiting access to promising new treatment regimens for tuberculosis disease and infection.
First-line antituberculosis therapy (ATT) for drug-sensitive tuberculosis is highly effective. However, in absence of wellcontrolled studies in pregnant women, first-line tuberculosis drugs have been listed as US Food and Drug Administration (FDA) pregnancy category C (ie, no adequate well-controlled human studies have been performed, but benefits may be acceptable despite potential risks) (Table 1) [17, 14] . Data regarding safety, tolerability, and the pharmacokinetics of tuberculosis drugs during pregnancy have not been collected or reported animal reproduction studies have failed to demonstrate a risk to the fetus and there are no AWC studies in humans or animal reproduction studies have shown an adverse effect but AWC studies in pregnant women have failed to demonstrate a risk to the fetus AND the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; C, animal reproduction studies have shown an adverse effect on the fetus, there are no AWC studies in humans OR there are no animal reproduction studies and no AWC studies in humans AND the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; D, there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans BUT the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; X, studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
FDA pregnancy letter categories will be eliminated during the next 3-5 years; instead, explanations concerning potential benefits and risks to the mother, fetus, and breastfeeding child will be provided based on available data [14] . b WHO tuberculosis drug groups are defined as follows: group 1, first-line agents; group 2, injectables; group 3, fluoroquinolones; group 4, oral bacteriostatic second-line agents; and group 5, agents with unclear efficacy. c Teratogenic in rodents given 1-2 times the maximum human dose.
d Teratogenic in rats given 3.5 times the human dose.
e Levofloxacin was not teratogenic in rats at 9.4 times the human dose or rabbits at 1.1 times the human dose. Moxifloxacin was not teratogenic in cynomolgus monkeys at 2.5 times the human dose, in rats at 0.24 times the human dose, or in rabbits at maximum human doses; rat and rabbit offspring, however, had delayed skeletal development. Temafloxacin, another quinolone, caused toxic cartilage effects in immature dogs [15] . f Equidoses of the maximum human dose in monkeys resulted in fetal growth retardation at plasma levels double that of human serum levels.
g Based on standard isoniazid dosing.
h Concentrated in rat breast milk.
i Based on studies in rats and rabbits. A small case series in humans (n = 6) showed no evidence of teratogenicity.
j Approved per the European Medicine Agency 2014 European public assessment report on delamanid [16] .
systematically, leading to inconsistencies in national and international treatment guidelines. The World Health Organization, for example, recommends the use of pyrazinamide during pregnancy in first-line ATT, but the US Centers for Disease Control and Prevention does not, owing to inadequate data on potential adverse fetal effects [18] [19] [20] . Multidrug-resistant (MDR) tuberculosis presents another challenge, because treatment options remain extremely limited during pregnancy. Most aminoglycosides, key in MDR tuberculosis treatment, are potentially ototoxic and nephrotoxic for the fetus [4] , and reproductive toxicity studies suggest that other second-line drugs for MDR tuberculosis, such as ethionamide-prothionamide, may have teratogenic potential (Table 1) . Although new compounds are in development and new oral drugs have been recently approved for MDR tuberculosis treatment in the United States (bedaquiline) and Europe (bedaquiline and delamanid), lack of safety or PK data during pregnancy severely limits their use in this population.
Next, a significant proportion of women who die of tuberculosis during pregnancy and postpartum are coinfected with HIV [1, 21, 22] . Notably, poor adherence to dual ATT and antiretroviral (ARV) therapy is problematic in this population [23, 24] . Combination tuberculosis/HIV regimens lead to increased pill burden, overlapping toxic effects, and drug-drug interactions, and pregnancy introduces gestational age-dependent changes in pharmacokinetics and drug tolerability [12, 13] . Rifamycins, for example, are essential in first-line ATT but alter the metabolism of ARVs recommended during pregnancy and concentrations of hormonal contraceptives, significantly complicating family planning for postpartum women with tuberculosis [25, 26] .
Finally, controlling the global tuberculosis epidemic requires preventing LTBI progression to active disease [27] . The World Health Organization currently recommends LTBI treatment among HIV-infected persons residing in high burden settings and in child contacts of persons with tuberculosis even when LTBI testing is unavailable [28] . Although pregnant women, particularly if HIV-infected, are at high risk of LTBI progression [10] , the standard regimen (daily isoniazid for ≥6 months) has never been systematically assessed for safety and PK data in pregnancy, though it seems safe in the small numbers studied [29] . Newer, shorter preventive regimens (eg, 12 once-weekly doses of isoniazid plus rifapentine; 1 month of daily isoniazid plus rifapentine) are now available or under study in nonpregnant populations, but pregnant women are excluded from clinical trials of these regimens [30, 31] .
Pregnant women should be allowed to access and benefit from advances in tuberculosis treatment. Pregnancy provides an important healthcare system entry point, at which women can be screened and treated for both tuberculosis and LTBI [32] [33] [34] [35] . Development of evidence-based treatment standards for pregnant women will require inclusion of this special population into studies of newly approved and investigational drugs for MDR tuberculosis. Because persons living with HIV are at highest risk of developing tuberculosis, there is a critical need to study drug interactions, optimal dosing of ATT, ARVs, and hormonal contraception [36, 37] in pregnant and postpartum women coinfected with HIV and tuberculosis. Studies of ARV therapy in pregnancy provide a good template for how ATT can be studied [26] .
We present (1) research considerations in pregnant and postpartum women based on literature review and (2) our consensus statements on 4 key research questions described below. We also propose clinical research priorities for the prevention and treatment of tuberculosis in pregnant and postpartum women.
METHODS

Consensus Statement Generation
In May 2013, the National Institutes of Health (NIH) convened an international expert panel of recognized HIV and tuberculosis clinicians, women's health researchers, opinion leaders, and community representatives in Bethesda, Maryland, to participate in a workshop, "Towards Earlier Involvement of Children and Pregnant Women in Trials of New TB Drugs." Panelists were tasked with generating consensus statements supporting pathways for accelerated inclusion of pregnant women and children (reported separately [38] ) in trials of tuberculosis drugs. Subject matter experts were identified based on review of published work; government, regulatory agency, and other participants were selected based on professional discipline with an aim to represent key perspectives concerning participation of pregnant women in tuberculosis drug trials (eg, legal and regulatory affairs, medical ethics, reproductive toxicity, and clinicians with experience in recruiting pregnant women into drug trials).
Discussions were framed by 4 guiding questions developed a priori by the organizing members (R. S. B., P. J. P.) and listed in "Results" section. A subgroup of panelists was tasked with conducting a preworkshop literature review (A. G., J. S. M., R. S. B., P. J. P., H. S.) that informed draft statements. Draft statements were then reviewed with panelists via a preworkshop teleconference, and subject matter experts addressed the guiding questions during the in-person workshop. Group consensus (>75% agreement among panelists) was required for consensus statement edits; experts from regulatory agencies participated in discussions as nonvoting panelists. Consensus statements were subsequently presented at the plenary session for discussion and finalized where needed via teleconference with all panelists.
Literature Search Strategy
The search strategy used PubMed, Medline, and Embase databases and included articles published in English between 1 January 2001 and 31 March 2013; websites for major regulatory bodies were searched for most recent versions of relevant guidelines/ guidance without date restriction. After the workshop, all articles published through 15 July 2015, regardless of publication date and language, were reviewed as retrievable and translated as needed; any relevant new information was included in the consensus discussion section. The following search terms were used: tuberculosis, anti-TB treatment, multidrug-resistant tuberculosis treatment, multidrug-resistant tuberculosis outcomes, pregnancy, postpartum, lactation/breastfeeding, pharmacokinetics, pharmacovigilance, clinical trials, drug development, HIV-infected, and developmental and reproductive toxicology.
RESULTS
Regulatory and Ethical Considerations for Research During Pregnancy and Postpartum
Nonclinical Studies
The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance [39] , endorsed by the FDA and the European Medicines Agency, states that nonclinical reproductive toxicity studies [40] and the standard battery of genotoxicity tests [41] should be conducted before including pregnant women in any phase of clinical trials (Supplementary Table and Supplementary  Figure 2) .
Clinical Studies
Before including pregnant women in phase II or III clinical studies, safety data from previous human exposure in nonpregnant individuals are needed [42, 43] . This is also specified in the Code of Federal Regulations [44] , (45CFR46, Subpart B), indicating that "Where scientifically appropriate, preclinical studies, including studies on pregnant animals, and clinical studies, including studies on nonpregnant women, have been conducted and provide data for assessing potential risks to pregnant women and fetuses." These regulations also require that studies with pregnant women hold out the prospect of direct benefit for the pregnant woman and/or the fetus, or if there is no prospect of direct benefit the studies entail no more than minimal risk and are aimed at developing important biomedical knowledge which cannot be obtained by other means.
Assessment of minimal risk can be variable and subjective, and can be particularly challenging in the setting of pregnancy [45] . Critical consideration of disease severity and treatment options are essential in the case of pregnant women with tuberculosis, particularly MDR tuberculosis. Potential benefit of research on new drugs for MDR tuberculosis in this population would be significant, and consideration must also be given to the consequences of off-label use in the absence of evidencebased guidance. It is safer to administer ATT during pregnancy in a research setting, given the rigorous safety monitoring, requisite informed consent requirements, and ability to confirm correct dosing [46] . Access to the benefits of research is an essential component of the ethical principle of justice in clinical research, and pregnant women have not benefited fairly from research given their under-representation in past trials [47, 48] . In November 2013, the FDA issued a draft guidance for pulmonary tuberculosis drug development, which specifically includes a section on drug development in pregnant women [49] .
PK Studies
The 2004 US FDA guidance on PK studies in pregnancy recommends that PK studies should be conducted for all drugs already used during pregnancy that have limited available safety and/or PK data and all new drugs with anticipated use during pregnancy [50, 51] [52] . Question 2: Which tuberculosis drugs and populations of pregnant and postpartum women should be studied? What are the highest priorities? There is no single ethical principle to guide prioritization of disease severity versus frequency of harms. The panel developed and prioritized a list of tuberculosis drug studies and populations of pregnant and postpartum women to be studied based on ethical, scientific, and public health considerations, as follows.
Priority 1: Studies of MDR tuberculosis and LTBI regimens that address safety, PK data by stage of pregnancy, and drugdrug interactions with the goal of shortening or simplifying existing regimens should be prioritized equally in (1) pregnant and postpartum women with MDR tuberculosis disease (rationale: MDR tuberculosis has high morbidity and mortality and results in poor maternal-fetal outcomes) and (2) HIV-infected pregnant women with LTBI (rationale: immune changes of pregnancy and HIV infection increase the risk of LTBI progression to tuberculosis; unlike with MDR tuberculosis, 20%-50% of HIV-infected pregnant women in tuberculosis-endemic countries have LTBI, and improving LTBI therapy in this population would have a large public health impact as a prenatal care intervention, reducing tuberculosis in mothers and young children).
Priority 2: Opportunistic studies of pregnant or postpartum women with drug-sensitive tuberculosis receiving a tuberculosis drug or regimen with limited data in pregnancy or postpartum. The rationale is that nonpregnant women participating in studies of investigational tuberculosis drugs may become pregnant during the study or may receive new and existing drugs in clinical practice. Opportunistic collection of safety and PK data will help improve tuberculosis management in pregnant and postpartum women (Table 2) [53, 54] .
Priority 3: Women of childbearing potential, including postpartum women, who take hormonal contraception and tuberculosis drugs. The rationale is that several hormonal contraceptives interact with tuberculosis drugs, particularly rifamycins. Tuberculosis drug trials often require that women of childbearing potential receive hormonal contraception for pregnancy prevention. Studies should evaluate the effect of tuberculosis drugs on concentration and efficacy of hormonal contraceptives and drug-drug interactions between ARVs, tuberculosis drugs, and hormonal contraception. To prevent pregnancies in these studies, nonhormonal contraception (eg, intrauterine devices and condoms) should be provided along with hormonal contraception.
Priority 4: Pregnant/postpartum women with tuberculosis disease or LTBI not meeting the above criteria. The rationale is that most women with tuberculosis have drug-sensitive tuberculosis disease, are HIV uninfected, and are being treated with a current standard regimen. Studies on the treatment history of tuberculosis and optimal treatment regimens in these populations could potentially have a high public health impact.
Question 3: Which candidate drugs/regimens should be prioritized? In accordance with the prioritization of populations described above, Table 3 displays the panel's prioritization of specific tuberculosis drugs/regimens to be studied in pregnant and postpartum women. All drugs and regimens have been or are currently being studied in phase IIb or III studies in nonpregnant populations.
Question 4: What are relevant trial designs to study tuberculosis drugs and regimens in pregnant and postpartum women?
PK data generated from nonpregnant trial participants provide limited information on drug disposition and drug safety in pregnancy [56, 57] . Based on the 2004 FDA guidance, PK studies are needed for drugs when, "pregnancy is likely to alter significantly the PK of a drug [50] ." To characterize the PK of tuberculosis drugs in pregnancy, the standard approach is to conduct intensive PK sampling in a small group of women in a stand-alone trial or in the context of a phase I/II treatment trial. Typically, intrasubject comparisons of PK parameters during pregnancy versus postpartum are made using a classic noncompartmental analysis approach. In phase III or IV trials or in clinical settings where pregnant women are already receiving the drug, investigators can use sparse sampling, generally defined as collecting <3 samples in a dosing interval, coupled with population PK analyses or opportunistic sampling from specimens drawn for clinical purposes (Table 2 ) [58] .
Cross-sectional studies can assess PK parameters of interest in parallel cohorts using the categorical variable of trimester during pregnancy. Longitudinal studies can incorporate serial assessments of PK by gestation, parturition, and lactation which allow for paired analyses and smaller sample sizes. Ultimately, logistical, statistical and analytical challenges of various trial designs should focus on informing treatment decisions for pregnant women.
Innovative PK/Pharmacodynamic Modeling to Estimate Target Doses for Pregnant Women
Sparse sampling strategies coupled with population PK analysis has the following advantages over intensive PK analysis in a small group of women: (1) reduction in blood sampling for individual participants; (2) improved ability to characterize variability in drug pharmacokinetics, including the effects of important covariates (eg, age, weight, race, HIV status, pharmacogenetics, and companion drugs) on PK parameters; and (Table 5 ) and have also been used to assess rifampin, isoniazid, and efavirenz concentrations and interactions.
In general, opportunistic PK sampling should involve the collection of as many samples as possible in a dosing interval (maximum of 5-7 samples spread equally in a dosing interval), but even a single sample can be useful if that is all that is feasible. If it is known ahead of time that opportunistic design is possible, relevant optimal sampling time windows can be determined. Dosing times must be recorded correctly, and pregnancy-related variables must be collected. In general, the more participants enrolled the better, but usually any design including >20 women is informative. (3) more power to characterize longitudinal changes in drug disposition. Mathematical modeling using PK data from pregnant women and PK or outcomes data from nonpregnant adults can be used to predict appropriate doses in pregnant women at different stages in pregnancy. Furthermore, population PK modeling can describe drug distribution in breast milk and in newborns. Physiologically based PK modeling can help predict exposures during pregnancy but is limited by current knowledge of the structural and functional changes occurring in the primary organs of drug disposition at different gestational stages [52, 57] .
Safety Monitoring and Pharmacovigilance
Clinical trials of tuberculosis drugs in pregnant women should include close maternal and fetal monitoring with clearly defined safety stopping rules and safety monitoring committee oversight. If a woman becomes pregnant during a trial, the tuberculosis drug's preclinical development toxicity profile, availability of alternative treatment regimens, and stage of pregnancy should determine whether trial continuation is offered. For women who continue in a trial, an additional informed consent process should be implemented that includes risks of untreated maternal disease, risks and benefits of the study agent, alternative treatment options, and embryofetal toxicity counseling. At minimum, data should be collected on pregnancy outcomes and the health of the mother and child (pregnancy registry use is encouraged). Data should include (1) pregnancy outcome, Drug companies developing new tuberculosis drugs should be encouraged to complete reproductive toxicity studies early in drug development, before beginning phase III trials; these data are needed to adequately inform decisions about the inclusion of pregnant women in subsequent clinical trials.
Specific trials of shortened treatment regimens for LTBI should be designed for pregnant women to facilitate treatment completion of regimens and reduce the risk of progression to tuberculosis disease during the high-risk pregnancy/postpartum period.
Targeted PK studies in pregnant and postpartum women should be nested into all trials to provide data on appropriate dosing of drugs during pregnancy and postpartum, when evidence-based dosing guidelines are not already available and particularly when pregnancy is likely to have a significant impact on drug disposition.
A registry should be established to accumulate data on the outcomes of pregnancies exposed to any tuberculosis drugs to allow monitoring of adverse events and to provide data to inform inclusion of pregnant women in clinical trials.
including live births, stillbirth, miscarriage, and pregnancy terminations; (2) small size for gestational age and low birth weight (<2500 g); (3) preterm birth; (4) congenital malformations; and (5) maternal and infant morbidity and mortality rates.
Pregnancy Registries
Evaluation of the risk of a particular drug exposure in pregnancy is commonly based on data collection from post-approval observational studies; drug data regarding potential teratogenicity usually is limited to nonclinical animal data. Pregnancy exposure registries are prospective, observational studies that monitor for evidence of teratogenicity and safety of medication. Welldesigned registries offer advantages over spontaneous, nonsystematic adverse event reporting by clinicians [59] . Regulatory guidance documents address study design, monitoring, evaluation, and data interpretation [17, 55, 59, 60] .
DISCUSSION
A summary of the consensus statements and priorities is shown in Table 4 . Despite substantial tuberculosis-related morbidity and mortality in pregnant/postpartum women and their infants, drug-sensitive tuberculosis, MDR tuberculosis and LTBI care is currently being provided without sufficient clinical trial data on drug safety and dosing. Studies in pregnant or postpartum women with tuberculosis are needed to provide accurate data to improve clinical treatment decisions. Engagement of trial sponsors, pharmaceutical companies, regulatory authorities, and health systems, including those in countries most affected by tuberculosis, are needed to support a pathway for accelerated inclusion of pregnant and postpartum women in trials of tuberculosis drugs. Clinical trials should reflect the public health priorities of the sites where they are conducted and occur in settings where similar trials are already being conducted in nonpregnant adults. Ideally, a plan for making new drugs available (ie, post-trial access) at the local level should be obtained before clinical trials commence. Establishing high-quality evidence demonstrating the efficacy and safety of new drugs can lead to advocacy in favor of rapid availability. Importantly, a mindset of presumed inclusion of pregnant and postpartum women into trials of promising tuberculosis agents should be adopted, as is already the case for pregnant women with HIV infection, who have significantly benefited from early inclusion in clinical trials. Involvement of local site investigators and community advisory boards and adequate support and oversight of trial conduct is critical to the process [61, 62] . Since this workshop, investigators have made some progress in initiating new studies and modifying existing studies to help fill the data void for tuberculosis management in pregnancy (Table 5) . A working group has been established to develop a pregnancy registry for tuberculosis drug studies. Only through responsible inclusion of pregnant and postpartum women in tuberculosis trials will we be able to provide clinicians and policy makers with the evidence needed to optimize their care globally.
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